Amgen Q3 Adjusted EPS $4.96 Beats $4.66 Estimate, Sales $6.90B Miss $6.94B Estimate
Portfolio Pulse from Benzinga Newsdesk
Amgen reported Q3 earnings of $4.96 per share, beating the analyst consensus estimate of $4.66 by 6.44%. However, the company's quarterly sales of $6.90 billion missed the analyst consensus estimate of $6.94 billion by 0.59%. This represents a 5.53% increase in earnings and a 3.77% increase in sales compared to the same period last year.
October 31, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amgen's Q3 earnings beat estimates but sales missed, which could lead to mixed market reactions.
While Amgen's earnings beat could be seen as a positive sign, the miss on sales could temper investor enthusiasm. The net impact on the stock price could be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100